[1] |
Asciak R, Rahman NM. Malignant pleural effusion: from diagnostics to therapeutics[J]. Clin Chest Med, 2018, 39(1): 181-193. DOI: 10.1016/j.ccm.2017.11.004.
doi: S0272-5231(17)30115-6
pmid: 29433714
|
[2] |
Tsou PH, Chiang PH, Lin ZT, et al. Rapid purification of lung cancer cells in pleural effusion through spiral microfluidic channels for diagnosis improvement[J]. Lab Chip, 2020, 20(21): 4007-4015. DOI: 10.1039/d0lc00663g.
doi: 10.1039/d0lc00663g
|
[3] |
王双珠, 王敏. 细胞块切片与常规细胞涂片免疫组化染色在胸腔积液病诊断中的价值[J]. 临床与实验病理学杂志, 2020, 36(2): 231-232. DOI: 10.13315/j.cnki.cjcep.2020.02.029.
doi: 10.13315/j.cnki.cjcep.2020.02.029
|
[4] |
Saha BK, Bonnier A. Cell block examination of pleural fluid, an underused and overlooked method for evaluation of malignant pleural effusion[J]. Am J Med Sci, 2022, 363(6): 556-557. DOI: 10.1016/j.amjms.2021.10.005.
doi: 10.1016/j.amjms.2021.10.005
|
[5] |
Park T. Crk and CrkL as therapeutic targets for cancer treatment[J]. Cells, 2021, 10(4): 739. DOI: 10.3390/cells10040739.
doi: 10.3390/cells10040739
|
[6] |
Xu C, Li L, Wang W, et al. Serum macrophage inhibitory cytokine-1 as a clinical marker for non-small cell lung cancer[J]. J Cell Mol Med, 2021, 25(6): 3169-3172. DOI: 10.1111/jcmm.16360.
doi: 10.1111/jcmm.16360
pmid: 33605059
|
[7] |
Schabath MB, Cote ML. Cancer progress and priorities: lung cancer[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(10): 1563-1579. DOI: 10.1158/1055-9965.EPI-19-0221.
doi: 10.1158/1055-9965.EPI-19-0221
|
[8] |
Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention[J]. Clin Chest Med, 2020, 41(1): 1-24. DOI: 10.1016/j.ccm.2019.10.001.
doi: S0272-5231(19)30080-2
pmid: 32008623
|
[9] |
Yu M, Gong ZP, Ma ZL, et al. CRKL promotes proliferation, migration, invasion of laryngeal squamous cell carcinoma[J]. Eur Rev Med Pharmacol Sci, 2020, 24(10): 5473-5480. DOI: 10.26355/eurrev_202005_21332.
doi: 10.26355/eurrev_202005_21332
|
[10] |
O'Neill RS, Emmanuel S, Williams D, et al. Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort[J]. World J Gastroenterol, 2020, 26(14): 1660-1673. DOI: 10.3748/wjg.v26.i14.1660.
doi: 10.3748/wjg.v26.i14.1660
|
[11] |
Liu X, Hu Y, Yu B, et al. CRKL is a critical target of Hh-GLI2 pathway in lung adenocarcinoma[J]. J Cell Mol Med, 2021, 25(13): 6280-6288. DOI: 10.1111/jcmm.16592.
doi: 10.1111/jcmm.16592
|
[12] |
Xu CH, Xue JS, Zhang XW, et al. The value of macrophage inhibitory cytokine-1 level in differentiating benign from malignant solitary pulmonary nodules[J]. Clin Respir J, 2018, 12(4): 1473-1478. DOI: 10.1111/crj.12693.
doi: 10.1111/crj.12693
pmid: 28834599
|
[13] |
陈阳育, 徐莉莉, 伍燕兵, 等. 血清及胸腔积液中四种肿瘤标志物联合应用对良恶性肿瘤鉴别诊断价值的评估[J]. 中华肿瘤防治杂志, 2021, 28(3): 212-222. DOI: 10.16073/j.cnki.cjcpt.2021.03.07.
doi: 10.16073/j.cnki.cjcpt.2021.03.07
|
[14] |
孙美琪, 张薇, 郝倩文, 等. 肿瘤标志物对良恶性胸腔积液鉴别的研究进展[J]. 实用肿瘤杂志, 2020, 35(3): 278-283. DOI: 10.13267/j.cnki.syzlzz.2020.03.018.
doi: 10.13267/j.cnki.syzlzz.2020.03.018
|
[15] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
doi: 10.3322/caac.21338
|
[16] |
Antonangelo L, Sales RK, Corá AP, et al. Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results[J]. Curr Oncol, 2015, 22(5): e336-e341. DOI: 10.3747/co.22.2563.
doi: 10.3747/co.22.2563
|
[17] |
吕明, 查娜, 邹玉凤, 等. 免疫细胞化学对浆膜腔积液中胃腺癌细胞、间皮细胞及恶性上皮型间皮瘤细胞鉴别诊断的应用价值[J]. 中华病理学杂志, 2018, 47(3): 180-185. DOI: 10.3760/cma.j.issn.0529-5807.2018.03.007.
doi: 10.3760/cma.j.issn.0529-5807.2018.03.007
|
[18] |
王艳华, 杨玉清. 细胞蜡块结合免疫细胞化学在浆膜腔积液病理诊断中的应用价值[J]. 中国药物与临床, 2020, 20(12): 2065-2066. DOI: 10.11655/zgywylc2020.12.071.
doi: 10.11655/zgywylc2020.12.071
|
[19] |
李文妹, 尤青海, 常远敏. 联合检测血清和胸腔积液Crk样蛋白、CEA在恶性胸腔积液诊断中的价值[J]. 临床肺科杂志, 2020, 25(6): 891-894. DOI: 10.3969/j.issn.1009-6663.2020.06.020.
doi: 10.3969/j.issn.1009-6663.2020.06.020
|